Barr, Paul M.

Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial

Jones, J. A., Mato, A. R., Wierda, W. G., Davids, M. S., Choi, M., Cheson, B. D., Furman, R. R., Lamanna, N., Barr, P. M., Zhou, L., et al. (2018) · The Lancet Oncology

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 383

Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies

Coutre, S. E., Byrd, J. C., Hillmen, P., Barrientos, J. C., Barr, P. M., Devereux, S., Robak, T., Kipps, T. J., Schuh, A., Moreno, C., et al. (2019) · Blood Advances

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 134

Treatment Effectiveness with Venetoclax-Based Therapy after Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study

Ghosh, N., Lamanna, N., Eyre, T. A., Coombs, C. C., Manzoor, B. S., Brown, J. R., Tuncer, H. H., Ujjani, C. S., Leslie, L. A., Roeker, L. E., et al. (2023) · Blood

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 6